Hemispherx Biopharma extends contract with Armada Health Care.
M2 PHARMA-August 19, 2015-Hemispherx Biopharma extends contract with Armada Health Care
(C)2015 M2 COMMUNICATIONS
United States-based Hemispherx Biopharma has extended its contract with Armada Health Care for two years.
It was reported yesterday that the agreement has been signed for the sales/marketing of Alferon N Injection, its Food and Drug Administration approved natural interferon, in the United States. According to the contract, the firm will produce and supply Alferon N Injection to physicians and patients through Armada's national network of specialty pharmacies.
Armada Health Care has agreed to provide ongoing sales and marketing to support the product's re-launch. Specialty Distributor, BioRidge Pharma (BRP), has received a two-year contract extension and will warehouse, ship, and distribute Alferon N Injection on an exclusive basis for United States sales.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 19, 2015|
|Previous Article:||DelMar Pharmaceuticals receives increased funding from National Research Council of Canada Industrial Research Assistance Program.|
|Next Article:||Alexion Pharma Canada receives approval for Strensiq from Health Canada.|